Catalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)

Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.

Original reporting
SEC EDGAR · Catalyst4, Inc.
Published Aug 18, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

Traders may monitor for follow-through buying or selling by related holders, but the filing alone does not provide new clinical, regulatory, or financial guidance.

02

Market read

A large 10% owner added roughly $50.1M of MPLT shares, which can modestly support sentiment but lacks fundamental catalysts in the text.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not disclose the investment thesis, timing constraints, or whether other holders are also changing positions.

Relevance 9/10Novelty 5/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction disclosure: Catalyst4, Inc. (10% owner) bought MPLT shares indirectly via an open-market purchase.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

Catalyst4, Inc. filed a Form 4 showing an indirect open-market purchase of 4.4M MPLT shares for about $50.1M.

Expected impact

Near-term impact is likely limited; any reaction would be sentiment-driven rather than driven by new operating information.

Evidence & confidence

Form 4 insider transactions can influence sentiment, but the article provides no new MPLT-specific business catalyst beyond the purchase details.

Market effects

Minimal, as this is a single-company ownership transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine portfolio rebalancing or indirect holdings mechanics, so it may not indicate a change in MPLT fundamentals.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the Form 4 insider transaction, ticker MPLT.

  • Catalyst4, Inc.

    Reporter of the Form 4, disclosed an indirect open-market purchase of MPLT shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in